Carey Ng - Dec 15, 2021 Form 3 Insider Report for Immix Biopharma, Inc. (IMMX)

Role
Director
Signature
/s/ Ilya Rachman as Attorney-In-Fact for Carey Ng
Stock symbol
IMMX
Transactions as of
Dec 15, 2021
Transactions value $
$0
Form type
3
Date filed
12/15/2021, 07:59 PM
Next filing
Dec 20, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMMX Convertible Note Dec 15, 2021 Common stock Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 30, 2019, the Registrant issued the Reporting Person a note in the amount of $750,000 which is payable upon request of the majority holders of like tenure notes on or after October 30, 2021. If the Registrant sells its equity securities prior to such date resulting in proceeds of not less than $10 million ("Qualified Financing"), then the note will automatically convert into such number of equity securities sold in the Qualified Financing at a conversion price equal to the lesser of (i) the price paid per equity security in the Qualified Financing multiplied by 0.80 and (ii) the quotient resulting from dividing $10 million by the number of outstanding shares of common stock immediately prior to the Qualified Financing (assuming the conversion of all securities convertible into common stock and the exercise of all outstanding options and warrants, including shares of common stock reserved and available for future grant under any equity incentive or similar plans).

Remarks:

Exhibit List: Exhibit 24.1 - Powers of Attorney